FOLD Amicus Corp: מקדם חוב לטווח ארוך להון

Amicus Therapeutics (FOLD) generates revenue through the sale of innovative treatments Galafold and Pombiliti, while its focus on rare metabolic pathologies ensures perpetual demand for therapy. The price history on the GURU.Markets chart reaches 1.64, confirming its status as a monopolist in the genetic disorders segment, which allows the company to maintain premium pricing due to mandatory insurance coverage for life-saving medications.

This metric measures the proportion of long-term liabilities relative to equity, determining the company's degree of financial autonomy and the risk of over-leverage. Analyzing the long-term financial dependency ratio allows an investor to assess the resilience of Amicus Therapeutics (FOLD) to the costs of developing rare disease therapies and the extent to which expansion rates depend on external borrowings while awaiting regulatory approval.